JUL 22, 2015
Phase 2 clinical trial results show that an intravitreal injection of an integrin peptide was more effective at releasing vitreomacular traction (VMT) or vitreomacular adhesion (VMA) than placebo.
Allegro Ophthalmics conducted a randomized, double-masked trial of its first-in-class integrin peptide therapy called Luminate in 106 patients. At 90 days after an injection, 65% of eyes achieved VMT or VMA release compared with 9.7% in the placebo group (P = 0.0129). No drug toxicity or intraocular inflammation was observed.
Allegro Ophthalmics is studying Luminate across multiple vitreoretinal indications. Phase 2 clinical trials are underway for diabetic macular edema and nonproliferative diabetic retinopathy.